What is NK cell therapy?

Your own natural-killer cells, expanded and returned — a licensed disease treatment, not a wellness product. What it is, who it is for, and what it cannot do.

The short answer

NK cell therapy is a form of adoptive immune-cell therapy. A sample of your blood is drawn, the natural-killer cell fraction is separated and multiplied in a licensed cleanroom over roughly two weeks, and the expanded cells are returned to you by infusion. Where it is lawfully delivered — as it is at Boao Lecheng in Hainan — it is delivered as disease treatment: an adjunct alongside oncology care, for a filed list of indications, to a patient a hospital panel has accepted. It is not a wellness infusion and it is not offered to healthy people to feel younger.

Everything below is the detail behind those four sentences: what the cells do, what the expansion actually involves, what the trial evidence supports, who gets declined, and the limits nobody selling this will volunteer.

What an NK cell is

Natural killer cells are a class of white blood cell in the innate immune system. Unlike T cells, which must first learn to recognise a specific target, NK cells patrol the body and destroy cells that have lost the normal “self” markers on their surface — a signature shared by many virus-infected cells and by tumour cells trying to evade detection. They are, in the immunologist’s phrase, the first responders. Their number and their activity decline with age, after chemotherapy or radiation, and in the months after major surgery, which is precisely when the body would most like to have them.

Autologous NK therapy is the attempt to restore that surveillance directly. A sample of your blood is drawn, the NK fraction is separated and expanded in a licensed GMP cleanroom over roughly two weeks — typically to many times its starting number — released only after passing viability, identity, sterility and endotoxin panels, and then reinfused. Autologous means the cells are your own: there is no donor, no matching, and no rejection question. How cell products are released, and what the zone requires →

What it is licensed for here

This is the part that matters most, and the part most often blurred elsewhere. At Boao Lecheng, autologous NK therapy is delivered by the zone’s tertiary hospitals as a disease-treatment program under the pilot zone’s clinical-stage licensing. The licensed indications, as filed by the treating hospital, are:

What is not on that list: longevity, rejuvenation, “immune optimisation” for the healthy, or any general wellness use. Mainland regulation now confines cell therapy to disease indications, and the zone’s hospitals hold their licences on that basis. If a clinic anywhere offers you NK cells to feel younger, that is a different — and, on the mainland, unlicensed — proposition. The retreat’s wellness side is built on the six-axis system, not on cells.

How a course runs

A full course therefore spans about five weeks. Guests handle this in one of three ways: an extended island stay that covers the whole course, the first infusion during the retreat with returns for the second and third, or — for those living in East Asia — three short visits. Hainan’s 30-day visa-free entry covers the first two comfortably; the treating hospital can support a stay extension on medical grounds where the course requires it.

Why NK activity falls, and when

The rationale for putting NK cells back rests on their going missing in the first place, and that decline is reasonably well characterised. NK cell number and cytotoxic function fall with age — part of the broader remodelling of the immune system usually called immunosenescence — and the functional loss is generally reported as steeper than the loss in raw count. Cytotoxic chemotherapy and radiation deplete the lymphocyte compartment directly, and recovery after a full course is measured in months rather than weeks. Major surgery produces its own transient suppression in the immediate post-operative window.

Those three facts are why the filed indications look the way they do. The programme is aimed at exactly the periods when surveillance is measurably weakest and the clinical stake is highest: after a resection, after checkpoint-inhibitor therapy, and after chemotherapy or radiation. That is a coherent rationale. It is not, on its own, evidence that the intervention changes outcomes — which is the next section.

What the evidence supports, and what it does not

Adoptive NK-cell transfer has been studied in humans for well over a decade. What is reasonably established is feasibility and tolerability: autologous NK products can be manufactured to specification and infused, and the toxicity profile in published early-phase work has generally been mild compared with T-cell therapies, without the cytokine-release and neurotoxicity syndromes that define CAR-T. That is a real and useful finding, and it is the finding this page rests on.

What is not established is efficacy in solid tumours. The clinical literature is dominated by phase I and small phase II studies with heterogeneous products, dosing and endpoints; results are mixed; and the best-supported clinical use of NK biology anywhere in the world is allogeneic — donor-derived — NK cells in haematological malignancy, which is a different product treating a different disease. The recognised obstacle in solid tumours is trafficking and persistence: infused NK cells have to reach a tumour and stay functional inside a microenvironment evolved to suppress them, and they are short-lived in circulation regardless.

The honest summary is that this is clinical-stage medicine in an area of genuine scientific momentum and genuinely incomplete evidence. That is precisely why the zone licenses it as a reported, indication-bounded programme rather than as a product, and why nobody here is permitted to promise you an outcome.

Autologous or donor-derived, and why the difference matters

Three letters cover two quite different things, and they are routinely marketed as one. Autologous means the cells are yours: drawn from you, expanded, returned to you. No donor, no tissue matching, no graft-versus-host question. Allogeneic means the cells came from someone else — a healthy donor, cord blood, or an engineered cell line. Allogeneic products can be made in advance and held ready, which is their commercial attraction, but they are a different risk profile and are regulated differently almost everywhere.

The programme here is autologous, and that is a constraint as much as a feature: nothing can be held in stock, every course requires its own two-week manufacturing run, and a failed batch means a re-run rather than a substitution from a freezer. If you are comparing offers, ask which one you are being sold. A provider who cannot answer that question in one word has told you something. NK cell therapy abroad: how the legal route, not the country, decides what you are buying →

Who is declined

The treating hospital’s panel applies the licensed inclusion criteria before anything else is discussed, and some guests are declined. The filed criteria are: age eighteen or over; an ECOG performance status of 0 to 2 (broadly, able to care for oneself and up and about for at least half of waking hours); a Child-Pugh score of 7 or below where liver function is relevant; an expected prognosis of at least three months; and negative screening for hepatitis B, hepatitis C, HIV and syphilis. Active uncontrolled infection, certain autoimmune conditions and some concurrent treatments are also exclusions.

Two further inclusion conditions are easy to miss and worth stating plainly. The diagnosis has to be established histologically and on imaging — CT, MRI, contrast-enhanced ultrasound, or liver-specific EOB-MRI depending on the site — and not on a marker trend alone; and blood count, liver function and renal function all have to sit inside the protocol’s ranges on the day. Women of childbearing age are required to use effective contraception for the duration of the course.

The filed exclusion list is more specific than most brochures suggest, and several items are absolute rather than a matter of panel judgement:

That last group is the one worth reading twice before you travel, because it has nothing to do with your cancer and everything to do with how the product is made and how you are staged. An albumin or aminoglycoside allergy is not something a general oncologist would think to raise, and it is discoverable from your own records before anyone books a flight. How a cell product is released here, and what gets refused →

What the infusion feels like, and the week after

Expanding immune cells and returning them means the cells then do something, and what they do is release signalling molecules. The filed protocol says so in plain terms, and says too that the reaction is not identical from one infusion to the next. What is reported most often is a fever, aching muscles, a headache or a feeling of pressure in the head, and tiredness. These are expected and self-limiting rather than a sign that something went wrong with the batch. Antipyretics and simple analgesics are permitted on the treating physician’s instruction, along with fluids and rest, and a sleep aid is not prohibited if the nights are disturbed. Anything you have taken in the previous month, supplements included, has to be declared, because some of it interacts.

What this is not is the cytokine-release and neurotoxicity picture that governs the consent conversation for CAR-T. That difference is one of the few things the published NK literature is genuinely confident about, and it is the reason a course runs as day care rather than as an inpatient admission. The wider question of how cell products are screened, released and refused in the zone is handled in the safety guide rather than repeated here.

The aftercare instructions are unglamorous and specific: stay warm and avoid chilling, rest, keep regular hours and do not sit up late; eat lightly and simply, go easy on spice, take seasonal fruit and vegetables; walk for a couple of hours after meals rather than training hard; drink one and a half to two litres of water a day; skip strong tea, coffee, tobacco and alcohol for the week; and stay out of hot baths, long soaks and hot springs for that same week. On an island sold partly on its hot springs, the last one is worth knowing before you book the spa afternoon — and it is the kind of instruction that appears in a protocol and never in a brochure.

What it cannot do

NK cell therapy does not replace surgery, chemotherapy, radiation or targeted drugs, and it is not offered as an alternative to any of them. It is an adjunct: an attempt to lower the odds of recurrence, or rebuild immune function, alongside the plan your oncologist has already set. It is clinical-stage medicine — lawful inside the zone precisely because outcomes are still being gathered — and every course is reported into China’s national real-world data program as a condition of the licence. No hospital in the zone may promise an outcome, and nor will we.

It is also not a one-time fix. NK cells are short-lived in circulation; the rationale for scheduled infusions, and for the follow-up measurements, is that the effect has to be maintained and checked, not assumed.

What drives the cost of an NK cell therapy course

We do not publish a figure for this, and neither does anyone else delivering it lawfully. The reason is structural rather than coy, and it is the same reason in every jurisdiction: a licensed programme cannot quote before a panel has accepted you, because until the indication is confirmed there is no protocol to price. What can be described honestly is the shape of the cost, which is more useful than a number anyway — it tells you what a quote ought to contain, and therefore lets you notice when one is missing something.

The cost of a course is assembled from four things, and they are quoted separately:

Two things follow. First, the honest comparison between two providers is not their headline figures but whether both are quoting all four lines: a number that leaves out the three assessment points and the day-care episodes is not cheaper, it is incomplete. Second, the mid-course and post-course panels are the part that keeps running after you fly home — the post-treatment series alone reaches out to six months — so settle in writing which of those visits are in the quote and which are not before the first infusion, rather than after it.

None of this is the retreat. The four-day longevity retreat is a separate and published thing, from $2,700, and its job is to establish whether a treatment programme is indicated at all; the treatment, if the panel accepts you, is quoted after that. What a longevity program in China costs, and what a hospital quote is built from →

Seven questions to ask any NK cell therapy provider

Why the zone, for this

Three things are true only here on the mainland. The therapy is licensed, delivered in tertiary hospitals rather than clinics, across five approval batches of cell and gene technologies. Four of the six technologies in the most recent batch are immune cell rather than stem cell products, which stem cell therapy in China: which conditions are approved, and where sets out batch by batch. The cells are manufactured on-site, in the hospitals’ own GMP facilities, so there is no cold-chain transfer between manufacturer and bedside. And outcome reporting is mandatory: the zone reports into a national real-world data program, which is the closest thing to a clinical trial framework a patient can enter outside of one. Why Boao Lecheng →

If you are weighing this against a programme in Vietnam, Japan or Thailand, the comparison worth making is not between countries but between the three legal routes an NK programme can travel on — a clinical trial, a licensed pathway, or physician discretion — because the route is what decides the oversight, the honesty of the quote, and whether anyone is permitted to decline you. NK cell therapy abroad: Vietnam, Japan, Thailand and China compared →

If you have had a solid tumour resected in the past two years, or are finishing checkpoint-inhibitor therapy, and your oncologist is open to an adjunct, write to us with the outline of your history. A care manager will tell you honestly, within one working day, whether the panel is likely to consider you — before you plan a trip around it.

Frequently asked

What is NK cell therapy?

Natural killer (NK) cells are white blood cells of the innate immune system that recognise and destroy abnormal cells without prior sensitisation. In autologous NK therapy, a patient's own NK cells are drawn, expanded in a licensed GMP facility for about two weeks, quality-released, and reinfused in a hospital day-care setting.

Who is NK cell therapy licensed for at Boao Lecheng?

As a disease-treatment program: adults after resection or checkpoint-inhibitor therapy for lung, colorectal, breast, liver, gastric, ovarian, pancreatic and prostate cancer, explicitly including recurrence-prevention populations, plus immune rebuild after chemotherapy or radiation. It is not offered for longevity, rejuvenation or general wellness.

How does a course of NK therapy run?

A course is typically three infusions, one every two weeks, each as a day-care hospital admission. Blood is drawn at the first visit, cells are expanded for about two weeks, and each batch passes viability, identity, sterility and endotoxin release testing before infusion.

How much does NK cell therapy cost, and why is there no price on this page?

No provider delivering NK cell therapy under a licence publishes a course price, because the protocol is not fixed until a panel confirms the indication. The cost of a course is built from four separately quoted parts: the cell product per infusion, the day-care hospital episode per infusion, assessment at three points (pre-treatment, mid-course every two weeks, and post-treatment at one, two, three and six months), and anything the panel combines with it. Comparing two quotes means checking that both contain all four, not comparing headline numbers. The four-day retreat that establishes whether treatment is indicated is separate and published, from 2,700 US dollars.

Who is declined for NK therapy?

The treating hospital's oncology panel applies the licensed inclusion criteria: age 18 or over, ECOG performance status 0 to 2, Child-Pugh score of 7 or below, a prognosis of at least three months, negative screening for HBV, HCV, HIV and syphilis, and blood count, liver and renal function within range. The filed exclusions include unresolved toxicity from earlier treatment, long-term immunosuppression after a transplant, severe organ dysfunction, active acute or uncontrolled infectious illness, pregnancy or breastfeeding, and known allergy to aminoglycosides, bacitracin, radiographic contrast media, or any component of the NK preparation including human serum albumin.

What are the side effects of NK cell therapy?

The reported effects are mild and self-limiting: fever, aching muscles, headache or a sensation of pressure in the head, and tiredness, and they vary between infusions. They are managed with antipyretics or simple analgesics on the physician's instruction, fluids and rest. Autologous NK therapy does not carry the cytokine-release or neurotoxicity syndromes associated with CAR-T, which is why a course is delivered as day care. Aftercare asks for warmth, rest, light food, one and a half to two litres of water a day, and no strong tea, coffee, tobacco, alcohol, hot baths or hot springs for a week.

Is NK cell therapy a cure for cancer?

No. It is clinical-stage adjunct treatment delivered under Boao Lecheng's pilot-zone charter with mandatory outcome reporting. It does not replace surgery, chemotherapy, radiation or your oncologist's plan, and no hospital in the zone may promise an outcome.

Can I come to Hainan just for NK therapy?

Candidacy is decided from your records and the retreat's day-two assessment, so the assessment comes first. A full course spans about five weeks; many guests take the first infusion during an extended stay and return for the others, or stay on the island between infusions.

Or download the Retreat Dossier (PDF) → — itinerary, inclusions, programs, practicalities.